Hemopurifier
Phase 1- Indications
- Advanced cancer, Metastatic cancer, Viral infections
Company intelligence / Profile preview
Currently conducting Phase 1 safety, feasibility, and dose-finding clinical trials of the Hemopurifier in cancer patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment in Australia and India. The first patient was enrolled in the Australian trial in November 2024. The company has also published preclinical data on the Hemopurifier in the Transplant Immunology journal in March 2025, suggesting expanded therapeutic potential beyond virology and oncology.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Aethlon Medical, Inc..